EnteroBiotix’s TrIuMPH Phase 2 trial of EBX-102-02 in IBS selected as a Poster of Distinction at Digestive Disease Week 2026
Glasgow, Scotland – 1 May 2026 – EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company developing microbiome-based therapies for gastrointestinal and metabolic diseases, today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in irritable bowel syndrome (IBS) have been selected as a Poster of Distinction at Digestive Disease Week (DDW) 2026. The designation is awarded to abstracts rated in the top 10% of all submissions accepted for poster presentation. DDW 2026 takes place at McCormick Place Convention Center in Chicago, Illinois, from 2–5 May 2026.
The poster presents integrated Phase 2a efficacy data across both IBS-C and IBS-D with associated mechanistic microbiome analyses. Together, the findings demonstrate clinically meaningful improvements in symptom severity and quality of life across subtypes, alongside alignment between clinical outcomes and microbiome changes, supporting EBX-102-02 as a potential disease-modifying therapy for IBS and informing the design of the ongoing Phase 2b RISE trial.
“Selection as a Poster of Distinction reflects the strength and clinical relevance of the TrIuMPH dataset and the growing scientific interest in full-spectrum microbiome restoration as a therapeutic strategy for IBS,” said Mr Paul Goldsmith MD FRCS, Consultant General and Upper GI Surgeon at Manchester University NHS Foundation Trust and Chief Investigator of the TrIuMPH study. “What is compelling about the data we are presenting at DDW is the breadth of the signal that we see across both subtypes, and signs of alignment between clinical benefit and the underlying microbiome changes - evidence consistent with its potential as a disease-modifying mechanism rather than symptomatic relief alone. These findings directly inform the Phase 2b RISE programme, which the company expects to begin dosing in Q2 2026.”
Presentation details
Title: A Randomised Double-blind Placebo-controlled Phase II Trial Assessing The Safety And Efficacy Of EBX-102-02, An Oral Full-spectrum Intestinal Microbiota Product In Patients With Irritable Bowel Syndrome With Constipation And Diarrhoea: The TrIuMPH Trial
Session: Irritable Bowel Syndrome: Treatment (Poster of Distinction)
Date and time: Saturday, 2 May 2026, 12:30–1:30 PM CDT
Location: McCormick Place Convention Center, Chicago, Illinois
Abstract number: 4485770
The abstract will be available via the DDW 2026 conference website.
-ENDS-
About EBX-102-02
EBX-102-02 is EnteroBiotix’s next-generation full-spectrum microbiome therapeutic, manufactured using proprietary processing technologies that enable safe, stable and orally delivered microbial ecosystem restoration. It is designed to deliver consistently high microbial diversity with a robust stability profile. It is not currently approved in any jurisdiction for clinical therapeutic use unless in a clinical trial or regulated programme.
About the TrIuMPH and RISE trials
TrIuMPH (“Treating IBS with an Intestinal Microbiota Product for Health”, ISRCTN65517362) was a UK-based, multicentre, randomised, double-blind, placebo-controlled Phase 2a study of EBX-102-02 in 122 adults with moderate-to-severe IBS-C or IBS-D. The study was delivered with support from the Functional Gut Clinic. Full results were announced on 8 January 2026.
RISE (“Restoring Intestinal Symbiosis for Efficacy in IBS”, ISRCTN15681288) is a randomised, double-blind, placebo-controlled Phase 2b interventional trial planned to enrol approximately 300 patients with moderate-to-severe IBS-C across UK sites. First patient dosing is anticipated in Q2 2026, with topline efficacy data expected in H2 2027.
About EnteroBiotix
EnteroBiotix is a clinical-stage biopharmaceutical company developing microbiome-based therapies for gastrointestinal and metabolic diseases. Using proprietary manufacturing and analytical technologies, the Company aims to create best-in-class orally delivered products that comprehensively restore microbial ecology and function. EnteroBiotix is headquartered in Glasgow, Scotland.
Media contacts
EnteroBiotix
Dr James McIlroy, CEO
info@enterobiotix.com
